Agentix and RTI announce worldwide exclusive license for NAFLD, NASH, T2D, obesity candidates

Agentix Corp.

License covers RTI small-molecule candidates for NAFLD, NASH, T2D, and obesity.
Agentix must complete Phase I trials by Jan 15, 2023; Phase II by Oct 2025; Phase III by Oct 2028.
Agentix plans to file IND with FDA in ~12 months; RTI to assist with IND-enabling toxicology and GMP manufacturing.
No financial terms disclosed; pre-clinical data show efficacy in animal models of metabolic diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.